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ABSTRACT 
Treatment switching often has a crucial impact on estimates of effectiveness and cost-effectiveness of new 
oncology treatments. Rank preserving structural failure time models (RPSFTM) and two-stage estimation (TSE) 
methods HVWLPDWHµFRXQWHUIDFWXDO¶LHhad there been no switching) survival times and incorporate re-censoring 
to guard against informative censoring in the counterfactual dataset. However, re-censoring causes a loss of 
longer term survival information which is problematic when estimates of long-term survival effects are required, 
as is often the case for health technology assessment decision making. We present a simulation study designed 
to investigate applications of the RPSFTM and TSE with and without re-censoring, to determine whether re-
censoring should always be recommended within adjustment analyses. We investigate a context where 
switching is from the control group onto the experimental treatment in scenarios with varying switch 
proportions, treatment effect sizes, treatment effect changes over time, survival function shapes, disease severity 
and switcher prognosis. Methods were assessed according to their estimation of control group restricted mean 
survival that would be observed in the absence of switching, up to the end of trial follow-up. We found that 
analyses which re-censored usually produced negative bias (i.e. under-estimating control group restricted mean 
survival and over-estimating the treatment effect), whereas analyses that did not re-censor consistently produced 
positive bias which was often smaller in magnitude than the bias associated with re-censored analyses, 
particularly when the treatment effect was high and the switching proportion was low. The RPSFTM with re-
censoring generally resulted in increased bias compared to the other methods. We believe that analyses should 
be conducted with and without re-censoring, as this may provide decision-makers with useful information on 
where the true treatment effect is likely to lie. Incorporating re-censoring should not always represent the default 
approach when the objective is to estimate long-term survival times and treatment effects. 
Key words: Treatment switching; treatment crossover; survival analysis; overall survival; oncology; health 
technology assessment; time-to-event outcomes; prediction; re-censoring 
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INTRODUCTION 
Treatment switching commonly occurs in randomised controlled trials (RCTs), whereby patients randomised to 
the control group are permitted to switch onto the experimental treatment during trial follow-up. Switching is 
permitted primarily due to ethical considerations, and the rationale for switching, its implications and analytical 
methods for adjusting for it have been the focus of much discussion in the literature.[1-4] Switching in trials is 
likely to continue to occur and can have a large impact on estimates of the effectiveness of new treatments if 
treatment is efficacious and no adjustments for switching are made. It is therefore important for regulators and 
health technology assessors to engage with methods that attempt to adjust for switching. Several statistical 
adjustment methods are available, but all make strong assumptions that are not possible to test perfectly. In 
addition, each of these methods can be applied in a multitude of ways and seemingly innocuous choices around 
how a particular method is applied can importantly affect the results they produce. This is sure to influence the 
thinking of decision makers when they seek to interpret the results of adjustment analyses, and may lead to a 
lack of trust in adjustment methods. It has been suggested that decision makers require manufacturers to 
describe and justify adjustment analyses in detail ± including the rationale for each application decision made ± 
in order that robust and informed decisions can be made.[5,6] 
Methods that have most commonly been used to adjust for treatment switching are Rank Preserving Structural 
Failure Time Models (RPSFTM), two-stage estimation, and inverse probability of censoring weighting 
(IPCW).[4,5] RPSFTM and two-stage estimation involve the estimation of counterfactual survival times ± that 
is, survival times that would have been observed if treatment switching had not occurred. The use of 
counterfactual survival times is problematic when censoring is present, and Robins and colleagues originally 
proposed re-censoring ± which will be described in the next section ± as a solution.[7,8] Branson and Whitehead 
subsequently suggested that re-censoring was not required,[9] but White responded to this by performing a 
simulation study in support of re-censoring.[10] 
Whether or not to apply re-censoring represents an application decision that can have a substantial impact on the 
results of RPSFTM and two-stage estimation analyses. In a recently published study, Latimer et al. presented a 
series of adjustment analyses applied to a trial analysing the effect of trametinib compared to chemotherapy in 
patients with metastatic melanoma.[11] A standard intention-to-treat (ITT) analysis resulted in a hazard ratio 
(HR) of 0.72 (95% confidence interval (CI) 0.52 to 0.98). However, 67% of control group patients had switched 
onto the experimental treatment. An RPSFTM analysis designed to adjust for the treatment switching gave a HR 
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of 0.38 (95% CI 0.15 to 0.95) when re-censoring was applied, and an HR of 0.49 (95% CI 0.25 to 0.96) when 
re-censoring was not applied. The HRs for a two-stage analysis to adjust for the treatment switching were 0.43 
(95% CI 0.20 to 0.96) with re-censoring and 0.53 (95% CI 0.29 to 0.97) without re-censoring. Such substantial 
differences in the point-estimate of the treatment effect can be critical particularly for estimates of the expected 
cost-effectiveness of new interventions ± overall survival benefit estimates are often the most influential 
parameters within cost-effectiveness models of cancer interventions.[12] Cost-effectiveness analyses are key 
factors in reimbursement decisions made on new healthcare interventions around the world.[13-16] 
It is generally recommended to apply re-censoring when using RPSFTM and two-stage estimation 
methods.[7,8,10,17] However, it is recognised that whilst re-censoring helps avoid one type of bias ± 
informative censoring ± it can result in a type of missing information bias when the treatment effect changes 
over time, or when long-term trends in hazards are not established in the short-term, because longer-term 
information is lost.[1,17-20] It may therefore be possible that in some situations analyses which do not re-censor 
are preferable to analyses which do. Currently, little is known about the impact of re-censoring in realistic 
scenarios, or how results should be interpreted when the choice of whether or not to re-censor has a large impact 
on the estimated treatment effect. Simulation studies have shown that adjustment methods produce varying 
levels of bias depending upon factors such as the switch proportion and the treatment effect size, but have only 
considered applications of adjustment methods that include re-censoring.[21-23] In this paper we conduct a new 
simulation study to investigate the performance of adjustment methods with and without applying re-censoring. 
Our objective is to determine whether it is possible to discern the likely impact of re-censoring in various 
scenarios, in order that expectations over the likely bias associated with analyses that do or do not re-censor can 
be informed. This should allow analysts and decision-makers to better interpret the results of adjustment 
analyses, enabling more constructive use of adjustment methods.     
METHODS   
Statistical adjustment methods 
The RPSFTM [24] and two-stage estimation methods [22] can be used to estimate counterfactual survival times 
in the presence of treatment switching in RCTs.  
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The simple one-parameter version of the RPSFTM splits the observed event time, ௜ܶ , for each patient into time 
spent on the control treatment, ஺ܶ೔ , and time spent on the intervention treatment, ஻ܶ೔ . For patients who are 
randomised to the intervention treatment, and who do not switch onto the control treatment, ஺ܶ೔  is equal to zero. 
For patients randomised to the control group who do not switch onto the intervention ஻ܶ೔  is equal to zero. 
However, for patients who switch treatments both ஺ܶ೔  and ஻ܶ೔  will be greater than zero. The RPSFTM method 
relates ௜ܶ  to the counterfactual survival time ( ௜ܷ) with the following causal model: 
 ௜ܷ ൌ ஺ܶ೔ ൅ ݁ట ஻ܶ೔        (1) 
݁ିట represents the acceleration factor (AF) associated with the intervention ± the factor by which treatment 
increases DQLQGLYLGXDO¶VH[SHFWHGVXUYLYDOWLPH7KH536)70DVVXPHVWKDWWKHUHLVDFRPPRQWUHDWPHQWHIIHFW
associated with the experimental treatment (i.e. that the treatment effect, ݁ట, is the same no matter when the 
treatment is received) and that if no patients received the experimental treatment average survival times in the 
randomised groups would be equal. Given these assumptions, g-estimation is used to estimate ߰, with the true 
value being that for which counterfactual survival times ( ௜ܷ) are independent of randomised group.[24] This is 
done by computing ௜ܷ for a range of values of ߰ and each time testing whether the ௜ܷ are independent of 
randomised group. 
The two-stage estimation method also involves estimating counterfactual survival times. The counterfactual 
survival model (1) is again used, but the two-stage estimation method estimates ߰ based upon an assumption of 
no unmeasured confounding. Under the simple two-stage method, it is assumed that treatment switching only 
occurs after a disease-related secondary baseline, such as disease progression. Then (assuming switching is only 
from the control group onto the experimental treatment), post-secondary baseline survival times in control group 
patients who switch onto the experimental treatment are compared to those in control group patients who do not 
switch, using a parametric accelerated failure time model (e.g. Weibull or Generalised Gamma), controlling for 
prognostic covariates measured at the secondary baseline time-point and including the switch indicator as a 
time-GHSHQGHQWYDULDEOHZKLFKHTXDOVµ¶DIWHUWKHWLPHRIVZLWFK$WUHDWPHQWHIIHFW߰) associated with 
switching is then obtained, and is incorporated into (1) to estimate counterfactual survival times in switching 
patients. Therefore, whilst the RPSFTM uses the randomisation and common treatment effect assumptions 
combined with g-estimation to account for potential prognostic differences between switchers and non-
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switchers, the two-stage method accounts for these differences by including important prognostic factors in the 
model used to estimate ߰. 
Censoring is problematic for the RPSFTM and two-stage method due to an association between treatment 
received, counterfactual censoring time, and prognosis. For ease of exposition, we assume the experimental 
treatment is beneficial, though similar arguments apply if it is harmful. The counterfactual survival model then 
involves shrinking survival times for all patients who receive the experimental treatment. For some patients, the 
event time (usually death) may not be observed ± instead it is censored. For these patients, the RPSFTM and 
two-stage methods involve shrunken censoring times. The amount by which survival or censoring times are 
shrunk depends upon the size of the treatment effect and the duration for which the experimental treatment is 
received. Counterfactual censoring times will be prone to informative censoring bias if either/both of the two 
following criteria are met: 
x If treatment switching decisions are related to prognostic factors;  
x If the duration of treatment is related to prognostic factors.   
Whilst both the RPSFTM and two-stage estimation seek to account for prognostic differences between switchers 
and non-switchers in their estimation of ߰, the potential for informative censoring in the counterfactual dataset 
remains because censoring times will be related to switching times, which may be related to prognostic factors. 
It has been suggested that possible bias associated with informative censoring can be avoided by breaking the 
dependence between the counterfactual censoring time and treatment received by re-censoring the 
counterfactual survival time associated with a given value of ߰ (that is, ௜ܷሺ߰ሻ) for all patients at the minimum 
of the administrative censoring time ܥ௜  and ܥ௜  ߰, representing the earliest possible censoring time over all 
possible treatment trajectories, ܦ௜כሺ߰ሻ. ௜ܷሺ߰ሻ is then replaced by ܦ௜כሺ߰ሻ if ܦ௜כሺ߰ሻ ൏  ௜ܷሺ߰ሻ.[7,8,17] In the 
context considered in this paper, where switching is from the control group onto the experimental treatment, 
survival or censoring times in the control group are re-censored at ܦ௜כሺ߰ሻ (that is, ܥ௜  ߰, when the treatment 
prolongs survival) if this is less than the observed survival or censoring time for non-switchers (since, for 
patients who did not switch, ௜ܷሺ߰ሻ ൌ ௜ܶ ), or less than counterfactual survival or censoring times ௜ܷሺ߰ሻ for 
switchers. 
It is straightforward to appreciate that the greater the treatment effect ߰, the greater the impact of re-censoring, 
and the more control group events will be lost as the survival data are artificially censored at a time-point earlier 
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than the follow-up times observed in the trial. A treatment effect calculated by comparing counterfactual control 
group survival times and observed experimental group survival times is therefore based upon shorter-term data 
for the control group (see Figure 1, which presents counterfactual survival curves with and without re-censoring 
from the trametinib example mentioned previously). If the treatment effect is not constant over time, using the 
re-censored survival data would result in bias if the objective is to estimate the overall longer-term treatment 
effect.[17] Similarly, if short-term control group data were extrapolated to estimate long-term survival, re-
censoring would be problematic if long-term trends in the hazard were not established within the timeframe of 
the re-censored dataset. Hence, whilst the re-censoring method aims to reduce bias associated with informative 
censoring in the counterfactual dataset, it may introduce another bias due to lost information, depending upon 
the objective of the analysis. It is common for regulatory and health technology assessment (HTA) agencies to 
attempt to estimate longer-term treatment effects for interventions that affect survival, with HTA agencies 
typically requiring estimates of lifetime treatment effects.[13-16] There has recently been considerable interest 
in moving away from the hazard ratio as a summary of the treatment effect, partly because treatment effects are 
often observed to change over time,[25,26] and it has been recognised that cancer populations may be 
characterised by complex hazard functions with turning points or important changes in trends in the longer 
term.[27-29] Therefore, there is a legitimate question as to whether re-censoring or not re-censoring is likely to 
produce less bias in an adjustment analysis, given an objective of estimating long-term survival times and 
treatment effects. 
We aim to investigate whether re-censoring or not re-censoring is likely to produce least bias in a range of 
realistic scenarios.  
Simulation study design 
We simulated independent datasets in which treatment switching was permitted, and in which the true survival 
times for each treatment option were known. Datasets with a sample size of 500 were simulated, with 2:1 
randomisation in favour of the experimental group, as observed in the trametinib trial (see Figure 1). We then 
applied each of the switching adjustment methods with and without re-censoring, and compared the bias in their 
estimation of restricted mean survival time (RMST) in the control group. We focussed on control group RMST 
because we simulated scenarios where switching was only in the control group and therefore the objective of the 
adjustment analysis was to estimate counterfactual survival times for the control group. In this context the 
adjustment methods do not adjust survival times in the experimental group ± adjustments are made solely to 
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control group survival times ± and therefore a direct comparison of control group RMSTs, rather than a 
comparative treatment effect, represents the most relevant and appropriate performance measure. For each 
method we also calculated the empirical standard error, root mean squared error and coverage associated with 
estimates of control group RMST. The study was designed such that the data simulated reflected data typically 
observed in clinical trials in the advanced/metastatic cancer disease area. The simulation study was conducted 
using Stata software, version 13.1.[30]   
Underlying survival times 
A joint survival and longitudinal model was used to simultaneously generate a continuous time-dependent 
FRYDULDWHUHIHUUHGWRDVµELRPDUNHU¶DQGVXUYLYDOWLPHV>31] similar to the approach taken in a previous 
simulation study.[21] The underlying biomarker level influenced survival and was influenced by treatment 
received, and observed values of the biomarker (which were subject to an error term) influenced the probability 
of treatment switching. Within the data-generating joint model, the longitudinal model for the underlying 
biomarker value for the ith patient at time t was:   
ܾ݅݋݉ܽݎ݇݁ݎ௜ሺݐሻ ൌ  ߚ଴೔ ൅ ߚଵݐ ൅ ߚଶݐ ൈ ݐݎݐ௜ ൅ ߚଷܾܽ݀݌ݎ݋݃௜            (2) 
where, 
ߚ଴೔ ?ܰሺߚ଴ǡ ߪ଴ଶሻ 
Here ߚ଴೔  is the random intercept, ߚଵ is the average rate of change of the biomarker for a patient in the control 
group, and ߚଵ ൅ ߚଶ is the average rate of change of the biomarker for a patient in the experimental treatment 
group. trti is a binary covariate that equals 1 when the patient is in the experimental group and 0 otherwise, 
badprogi is a binary covariate that equals 1 when a patient has poor prognosis at baseline and 0 otherwise, and ߚଷ is the change in the intercept for a patient with a poor prognosis compared to a patient with a good prognosis. 
We simulated data in which biomarker observations were made at randomisation and at 21 day intervals after 
randomisation. Biomarker observations were subject to an error term with a standard normal distribution with 
mean 0 and variance ߪଶ. 
For the majority of our scenarios we used a 2-component mixture Weibull baseline survival function and the 
general survival simulation framework described by Crowther and Lambert (2013)[31] to simulate survival 
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dependent on a time-varying biomarker. Simulating using a mixture model allows us to simulate complex 
hazard functions, which is important given the recognition that real-world survival data frequently does not 
follow standard parametric distributions.[32] The model can be written as:  
 ܵ଴ሺݐሻ ൌ ݌ ሺെߣଵݐఊభሻ ൅ ሺ ? െ ݌ሻ ሺെߣଶݐఊమሻ  (3) 
where  ߣଵǡ ߣଶ ൐  ?  and ߛଵǡ ߛଶ ൐  ? are scale and shape parameters, respectively. The mixture parameter, p, with  ? ൑ ݌ ൑  ?, represents the contribution of the first Weibull to the overall survival model, and   ? െ ݌ represents 
the contribution of the second Weibull. The related baseline hazard function is: 
݄଴ሺݐሻ ൌ  ఒభఊభ௣௧ംభషభୣ୶୮ሺିఒభ௧ംభሻାఒమఊమሺଵି௣ሻ௧ംమషభୣ୶୮ሺିఒమ௧ംమሻ௣ ୣ୶୮ሺିఒభ௧ംభሻାሺଵି௣ሻ ୣ୶୮ሺିఒమ௧ംమሻ            (4) 
The linear predictor of the survival model was incorporated as follows: 
 ݄௜ሺݐሻ ൌ ݄଴ሺݐሻ ሾߜଵݐݎݐ௜ ൅ ߟW ൈ ݐݎݐ௜ ൅ ߜଶܾܽ݀݌ݎ݋݃௜ ൅ ߙܾ݅݋݉ܽݎ݇݁ݎ௜ሺݐሻሿ      (5) 
where ߜଵ is the direct effect of treatment at time 0, Șis the rate at which the direct effect of treatment changes 
with time, ߜଶ is the impact of poor prognosis, and Į is the coefficient of the underlying biomarker level.  
Disease progression times were simulated to equal survival times multiplied by a value from a beta distribution 
with shape parameters (5,10). We assumed that patients had consultations with their clinician every 21 days, and 
that disease progression was observed to have occurred at the first consultation following the actual progression 
event.  
We simulated random entry into the study. The maximum administrative censoring time was set at 548 days (1.5 
years), and patients in the control group had a random uniform entry time from 0 to 183 days ± hence their 
administrative censoring times ranged from 365 to 548 days.  
,QRQHVHWRIVFHQDULRVZHH[FOXGHGWKHµt¶WHUPVIURPWKHGDWDJHQHUDWLQJPHFKDQLVPDQGXVHGDVLQJOH:HLEXOO
model rather than a mixture model, in order to test the different methods in instances with a simplified survivor 
function and a constant treatment effect (i.e. with proportional hazards) over time. Specifically, ߙ and ߟ were set 
to zero. We continued to simulate the time-dependent biomarker covariate, but this no longer affected survival. 
In these scenarios re-censoring should be less prone to bias, because long-term trends in the hazard are 
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established in the short-term and the treatment effect is constant. Comparing results from scenarios with a 
complex survivor function to scenarios with a simplified survivor function and treatment effect should show 
how sensitive methods that apply re-censoring are to these complexities.  
Scenarios were ordered such that low numbers were associated with parameter values that were unlikely to 
result in major biases for the adjustment methods, and high numbers assessed scenarios where bias was more 
likely to be a problem. For instance, Scenario 1 had a simple, single Weibull survival model, a low treatment 
effect and a low switching proportion. Scenario 13 provides a more representative illustration of the scenarios 
tested, characterised by a mixture Weibull survival model and a high, time-dependent treatment effect. 
Parameter values for the mixture Weibull survival model and the longitudinal biomarker model in Scenario 13 
were: 
ߚ଴ ൌ  ? ?ǡ ߪ଴ଶ ൌ  ?ǡ Ⱦଵ ൌ  ?Ǥ ? ?, ߚଶ ൌ െ ?Ǥ ? ? , ߚଷ ൌ  ?Ǥ ?, ߪଶ ൌ  ?,  ߜଵ ൌ െ ?Ǥ ? ?, ߜଶ ൌ  ?Ǥ ?, ߙ ൌ  ?Ǥ ? ?, ߣଵ ൌ ?Ǥ ? ? ? ? ?, ߛଵ ൌ  ?Ǥ ?,  ߣଶ ൌ  ?Ǥ ? ? ? ? ?, ߛଶ ൌ  ?Ǥ ? ,݌ ൌ  ?Ǥ ?, ߟ ൌ  ?Ǥ ? ? ?.   
An example of the Kaplan-Meier curves and hazard function produced by the simulation model (in the absence 
of treatment switching) from a single simulated data set using Scenario 13 parameter values is presented in 
Figure 2. We simulated a hazard function that was initially low, then steadily increased before decreasing 
towards the end of the trial follow-up. This is similar to the data simulated in our previous study,[21] and we 
believe that this is typical of the types of hazards observed in a metastatic oncology RCT setting: initial hazards 
are likely to be low, because trial inclusion criteria dictate that trial participants usually have relatively good 
prognosis. The seriousness of the disease dictates that hazards are likely to rise, before falling in the longer term 
as those who remain alive are of relatively better prognosis. The resulting Kaplan Meier curves are also 
reminiscent of those observed in the trametinib in metastatic melanoma example presented in Figure 1. 
Treatment effect in the experimental group 
For the majority of scenarios investigated we cannot summarise the treatment effect experienced in the 
H[SHULPHQWDOJURXSXVLQJDVLQJOHYDOXHEHFDXVHRXUKD]DUGIXQFWLRQLQFOXGHVµt¶WHUPVParameter values for 
the survival and biomarker models were chosen to generate realistic survival times and treatment effects, and 
these were varied in sets of scenarios to investigate the impact of different treatment effect sizes on the 
performance of the adjustment methods. Primarily, we investigated a treatment effect that initially increases 
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during the period of greatest hazard, before falling in the longer-term. We believe that this is representative of a 
realistic treatment effect, which falls in the longer-term when the initial treatment effect may have worn off, or 
when only better prognosis patients remain alive. 
,QWKHVHWRIVFHQDULRVWKDWH[FOXGHGWKHµt¶WHUPVIURPWKHGDWDJHQHUDWLQJPHFKDQLVPWKHWUXHWUHDWPHQWHIIHFW
was known, with ߜଵ representing the log hazard ratio. In scenarios that incorporated a time-dependent treatment 
HIIHFWWRJLYHDQLGHDRIWKHVL]HRIWKHWUHDWPHQWHIIHFWZHFDOFXODWHGWKHµDYHUDJH¶+5DQGAF (and߰) by 
generating scenario-specific survival data for a large number of patients (1 000 000) without applying switching, 
and by fitting Cox and RPSFTM models to this.      
The switching mechanism 
Only patients in the control group could switch treatments, and switching could only occur during the three 
consultations immediately following disease progression ± switching was not permitted before disease 
SURJUHVVLRQWRUHIOHFWWKHWUHDWPHQWVZLWFKLQJW\SLFDOO\VHHQLQPHWDVWDWLFFDQFHUWULDOV>@'XULQJWKLVµDWULVN¶
period, the probability of switching declined for each individual patient with each simulated consultation, which 
were DVVXPHGWRRFFXUHYHU\GD\V7KHSUREDELOLW\RIVZLWFKLQJGXULQJWKHµDWULVN¶SHULRGZDVFDOFXODWHG
using a logistic function and depended upon the time of observed disease progression, and the observed 
biomarker value at that time-point. In reality, switching is highly likely to be related to prognosis and therefore 
in half of our simulated scenarios patients with relatively good prognosis were more likely to switch, and in the 
other half switching was more likely in patients with relatively poor prognosis. Switching probabilities were 
varied to test different switching proportions. Further details on the probability of switching in different 
simulated groups are presented in Appendix A.   
Treatment effect in switchers 
For patients who were simulated to switch from the control treatment onto the experimental treatment, the 
period after switching was multiplied by a factor (Ȧ) to estimate survival times incorporating the impact of 
switching ( ௭ܶ೔), using the following approach:    
 ௭ܶ೔ ൌ ஺ܶ೔ ൅ ߱ ൈ ஻ܶ೔        (6) 
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where ஺ܶ೔  represents the time of switching and ஻ܶ೔  represents the survival time after the switch point that was 
simulated to occur in the absence of switching. This is the same as the accelerated failure time model presented 
in (1), but here we denote the treatment effect as ߱ rather than ݁ିట.   
The magnitude of Ȧ was varied across scenarios to represent relative reductions in the average treatment effect 
in switchers compared to the experimental group (in terms of an AF) of 0% and 20%. This allowed us to test 
VFHQDULRVLQZKLFKWKHµFRPPRQWUHDWPHQWHIIHFW¶DVVXPSWLRQGLGDQGGLGQRWKROG)RULQVWDQFHLQVFHQDULRV
where the common treatment effect assumption was simulated to hold, Ȧ was set to equal the previously 
estimated scenario-specific average experimental group AF (that is, ݁ିట), ensuring that the treatment effect 
received by switchers was the same as the average effect received in the experimental group. In scenarios where 
a 20% treatment effect reduction in switchers was simulated Ȧ was set to equal ሺሺ݁ିట െ  ?ሻ ൈ  ?Ǥ ?ሻ ൅  ?. In 
scenarios where there was a time-dependent treatment effect, the common treatment effect assumption did not 
hold in the truest sense even when the treatment effect received by switchers was the same as the average 
treatment effect in the experimental group, because the treatment effect in the experimental group was time-
dependent. However, in the set of scenarios that did not incorporate a time-dependent treatment effect the 
common treatment effect assumption did truly hold.  
Scenarios investigated 
The simulated data generating mechanism had several variables for which values had to be assumed. These are 
listed in Appendix B, together with details on how they were across scenarios. Scenarios were devised in order 
to cover key variables that were likely to change in trials in the real world, and also to test the sensitivities of the 
different adjustment methods with respect to their key assumptions. Scenarios were run varying the following 
characteristics: 
x Switcher prognosis: good prognosis more likely to switch; poor prognosis more likely to switch;  
x Common treatment effect (CTE): no CTE (20% relative treatment effect reduction received by switchers as a 
proportion of the average AF in the experimental group) ; CTE (0% relative treatment effect reduction) 
x Treatment effect: low (average HR/AF/߰ under the incorrect assumption of proportional treatment effects 
approximately 0.80/1.13/-0.12); high (average HR/AF/߰ approximately 0.56/1.85/-0.62)  
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x Complexity of the survivor function and time dependency of treatment effect: simple (single Weibull model, Ƚ ൌ  ?Ǥ ? ?, Ʉ ൌ  ?Ǥ ? ? ?); moderate (mixture Weibull model, Ƚ ൌ  ?Ǥ ? ?, Ʉ ൌ  ?Ǥ ? ? ?); high (mixture Weibull model, Ƚ ൌ  ?Ǥ ? ?, Ʉ ൌ  ?Ǥ ? ? ?) 
x Severity of disease: low (restricted mean survival in control group approximately 357 days, administrative 
censoring proportion approximately 40-50%); high (restricted mean survival in control group approximately 228 
days, administrative censoring proportion approximately 17-25%) 
x Switch proportion: low (approximately 25% of control group patients who experienced disease progression) ; 
moderate (approximately 55% of control group patients who experienced disease progression)  
Using a 2x2x2x3x2x2 factorial design resulted in a total of 96 scenarios. The scenarios were numbered 1-96 
with all levels of one factor nested inside one level of the next factor, following the order listed above. One 
thousand simulations were run for each scenario, with each simulation producing a dataset of 500 patients 
randomised at a 2:1 ratio to the experimental and control groups respectively. Scenario settings are detailed in 
Appendix C.  
Adjustment methods compared 
To provide context on the performance of the adjustmHQWPHWKRGVZHSUHVHQWUHVXOWVIURPDµ1R6ZLWFKLQJ¶
analysis, representing the results of a standard ITT analysis (that is, an unadjusted estimate of control group 
RMST) undertaken on the simulated dataset before switching was applied. This does not represent a feasible 
estimator, but provides a useful upper bound for adjustment method performance which may be considered a 
µJROGVWDQGDUG¶. We also present a standard ITT analysis after switching was applied. 
For the RPSFTM we used a log-rank test within the g-estimation procedure using the Stata command strbee.[33] 
We included the RPSFTM with and without re-censoring (referred to as RPSFTM and RPSFTMnr 
respectively).  
We applied the two-stage method using a Weibull model, used disease progression as the secondary baseline 
time-point, and included covariates for switching, baseline prognosis group, observed biomarker value at time 0, 
observed time-to-disease progression, and observed biomarker value at disease progression. We included the 
two-stage method with and without re-censoring (referred to as TSE and TSEnr respectively).  
Performance measures 
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We used control group restricted mean survival time (RMST) as our true value, or estimand, upon which to base 
our performance measures. Our simulated survival function was not analytically tractable so for each scenario 
we simulated data for 1 000 000 patients without incorporating treatment switching, and we estimated the 
RMST at 548 days (the maximum administrative censoring time in the simulated datasets). Because this value is 
the product of a simulation rather than a calculation it is prone to error, but this is likely to be extremely minimal 
given the large number of patients simulated.  
To estimate RMST at 548 days for each of the adjustment methods, we could not simply calculate the area 
under the counterfactual Kaplan-Meier curve because this may restrict the mean estimation to too short a time 
period, particularly for methods that apply re-censoring. Instead, we used what we believe is the most 
appropriate approach given the context that these methods are usually used in ± that is, for health technology 
assessment. TSE, TSEnr, RPSFTM and RPSFTMnr each provide counterfactual datasets, to which we fitted 
flexible parametric models in order to obtain the survivor function extrapolated to 548 days. The Stata command 
stpm2 was used to fit the models on the log cumulative hazard scale, with 3 knots placed at equally spaced 
centiles of the distribution of the log survival times.[34] Where the final observed survival time was less than 
548 days, the RMST at 548 days was estimated through a linear extrapolation from the last knot. This is in line 
with recommendations made in the UK for undertaking survival modelling in the absence of proportional 
hazards.[35,36] To estimate confidence intervals (CIs), counterfactual datasets were derived for the lower and 
upper 95% CIs of the estimated treatment effect ሺ߰) for each of the adjustment methods. Then flexible 
parametric models were fitted as described above to estimate 95% CIs for RMST at 548 days.  
We evaluated the performance of methods according to the percentage bias in their estimate of control group 
RMST at 548 days. Percentage bias was estimated by taking the difference between the mean estimated RMST 
and the true RMST and expressing this as a percentage of true RMST.[37] The root mean squared error (RMSE) 
of the percentage bias was calculated to provide information on the variability of estimates in combination with 
percentage bias. The empirical standard error (SE) of the RMST estimate was also calculated for each method, 
as was coverage, defined as the proportion of simulations where the 95% confidence interval of the RMST 
contained the true RMST. Convergence was measured, defined as the proportion of times that each method 
resulted in an estimate of control group RMST. Percentage bias, RMSE, empirical SE and coverage were 
calculated based upon simulations in which convergence occurred. Monte Carlo (MC) standard errors were also 
calculated for each performance measure, for each method.   
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RESULTS 
First we present detailed results from 4 important scenarios, chosen to highlight key drivers of the results. We 
then summarise how these results relate to the full range of scenarios tested. Finally, we draw together key 
findings on within-method performance ± comparing TSE to TSEnr and RPSFTM to RPSFTMnr, followed by 
key findings on between-method performance.  
A summary table describing the characteristics of each scenario is presented in Appendix D. Appendices E, F 
and G present the percentage bias, empirical standard error and RMSE respectively across all scenarios for each 
method.  
Detailed results from key scenarios 
Table 1 presents detailed results from Scenarios 9 and 13. Scenario 9 incorporated a low switch proportion, a 
low treatment effect, low disease severity, a moderately complex survivor function, and violated the common 
treatment effect assumption. As expected, the ITT analysis estimated a higher control group RMST than would 
have been observed in the absence of treatment switching, but bias was low ± equivalent to a percentage bias of 
1.2%. The adjustment methods ± except the RPSFTM ± led to reduced bias. The RPSFTM and TSE analyses 
that applied re-censoring both under-estimated control group RMST, with the level of bias more appreciable for 
the RPSFTM (percentage bias -1.2%, compared to -0.3% for TSE). In contrast, RPSFTMnr and TSEnr analyses 
over-estimated control group RMST (percentage bias 0.4% for the RPSFTMnr and 0.7% for the TSEnr).  
The only substantive difference between Scenario 9 and Scenario 13 was that the treatment effect was higher in 
Scenario 13, with an average HR of 0.57, compared to 0.81 in Scenario 9. Percentage bias increased appreciably 
for the ITT analysis and for each of the adjustment methods in Scenario 13. Methods that applied re-censoring 
continued to under-estimate control group RMST (percentage bias -1.6% and -3.8% for TSE and RPSFTM 
respectively), and methods that did not apply re-censoring continued to over-estimate control group RMST 
(1.4% and 0.9% for TSEnr and RPSFTMnr respectively).  
Table 2 presents detailed results from Scenarios 57 and 61. These were similar to Scenarios 9 and 13, with the 
only substantive difference the switching proportion, which was increased to approximately 57% of at-risk 
patients (39% of all control group patients).  
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The increased switching proportion had an important impact, leading to increased bias, with the relative effect 
on the different adjustment methods dependent on the size of treatment effect. Comparing Scenario 57 to 
Scenario 9 (scenarios in which the treatment effect was small), the impact of the increased switching proportion 
was most important for the adjustment methods that re-censored, with percentage bias approximately doubled in 
Scenario 57 (percentage bias -1.1% and -2.0% for TSE and RPSFTM respectively). Percentage bias also 
increased for TSEnr and RPSFTMnr in Scenario 57, but the difference was not as substantial (percentage bias 
0.8% and 0.7% for TSEnr and RPSFTMnr respectively). Bias was further increased for each of the adjustment 
methods in Scenario 61, in which both the treatment effect and the switching proportion were high, but the 
impact in this scenario was relatively more important for the adjustment methods that did not re-censor. For 
TSEnr and RPSFTMnr bias approximately doubled compared to Scenario 13 (percentage bias 3.0% and 2.1% 
for TSEnr and RPSFTMnr respectively), whereas for TSE and RPSFTM the increase in bias was more marginal 
(percentage bias -1.9% and -5.3% for TSE and RPSFTM respectively). 
In Scenarios 9, 13, 57 and 61 the TSE, TSEnr and RPSFTMnr methods produced similarly low levels of bias, 
with the RPSFTM producing a higher level of bias. The direction of the biases remained the same in each 
scenario ± applications that re-censored resulted in negative bias and those that did not re-censor resulted in 
positive bias. TSE, TSEnr and RPSFTMnr produced lower percentage bias than the ITT analysis, but the 
RPSFTM did not when the switching proportion was low. Levels of variability associated with the different 
adjustment methods differed importantly. Higher levels of bias were not always associated with higher RMSEs. 
)RULQVWDQFHLQHDFKVFHQDULR76(QUSURGXFHGOHDVW506(DVLGHIURPWKHJROGVWDQGDUGµQRVZLWFKLQJ¶
analysis, and both the TSEnr and RPSFTMnr produced appreciably lower RMSE than TSE and RPSFTM, even 
when the methods that re-censored resulted in lower percentage bias. This reflects the fact that the empirical SE 
of the percentage bias differed substantially between methods. Two-stage and RPSFTM methods that re-
censored produced empirical SEs that were approximately fifty percent larger than those associated with 
methods that did not re-censor.  
Coverage was poor for all the adjustment methods, although methods that re-censored provided better coverage 
than those that did not. Convergence was achieved with all of the adjustment methods in each of the scenarios.  
Results from other scenarios  
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The overall patterns in our results are illustrated in Figures 3-5, which present nested loop plots for percentage 
bias, empirical SE and RMSE.[38] More detailed barplots for each of these performance measures are presented 
in Appendices E, F and G. The results presented above provide a good basis for reporting the results of the 
remaining scenarios ± particularly those observed in scenarios where the complexity of the survivor function 
was moderate or high. The characteristics that had the most impact on the performance of the adjustment 
methods were the complexity of the survivor function, the switching proportion, and the size of the treatment 
effect. 
When the survivor function was simple, with a constant treatment effect over time, the adjustment methods 
generally produced similar and low levels of bias, with the only exception being the RPSFTM which produced 
higher levels of bias when there was a high, non-common treatment effect and a high switching proportion. The 
range of empirical SE and RMSE produced by the different adjustment methods was narrower than in other 
scenarios, but TSEnr consistently produce the lowest values. RPSFTM produced negative bias in the vast 
majority of scenarios and TSEnr usually produced positive bias. The direction of bias was more varied for the 
TSE and RPSFTMnr methods. TSE generally produced negative bias when poor prognosis patients were more 
likely to switch, and generally produced positive bias when good prognosis patients were more likely to switch. 
RPSFTMnr produced positive bias in the majority of these scenarios, but often produced negative bias when the 
common treatment effect assumption was violated.   
When the complexity of the survivor function was moderate or high, with a decreasing treatment effect over 
time, the performance of the adjustment methods varied much more widely, with bias approximately doubled in 
size compared to that observed in scenarios with a simple survivor function and a constant treatment effect. 
TSEnr produced positive bias (over-estimating control group RMST) in all 64 of these scenarios. RPSFTMnr 
produced positive bias in all but 4 scenarios ± and where it produced negative bias this was of a similar size to 
the associated MC error. RPSFTM produced negative bias (under-estimating control group mean survival) in all 
of 64 scenarios, and TSE produced negative bias in the vast majority of scenarios, but occasionally produced 
positive bias when the treatment effect was low (though in these scenarios the positive bias was often of a 
similar size to the associated MC error).  
Percentage bias was increased for all methods when the treatment effect was high. Similarly, percentage bias 
was increased for all methods when the switching proportion was moderate as opposed to low, although the 
impact was much more substantial for methods that did not apply re-censoring. When the switching proportion 
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was low, the size of the treatment effect was less important for TSEnr and RPSFTMnr, but remained a crucial 
determinant of the bias associated with TSE and RPSFTM. 
Based upon Figure 3, high disease severity appears to be an important driver of bias. However, it is important to 
note that whilst the average hazard ratio associated with treatment was (by design) held the same in equivalent 
scenarios characterised by high and low disease severity, the average acceleration factor was higher in high 
severity scenarios. Given that the RPSFTM and TSE methods use accelerated failure time models this is 
important, and means that the impact of disease severity cannot be interpreted in isolation ± the observed 
increase in bias may be due to the increased disease severity, or may be due to the increased acceleration factor.  
The common treatment effect characteristic had an impact on the RPSFTM (bias reduced when there was a 
common treatment effect) and RPSFTMnr (bias increased when there was a common treatment effect), but it did 
not affect the TSE and TSEnr methods. Whether poor prognosis patients or good prognosis patients were more 
likely to switch did not have an impact on RPSFTM and TSE methods. The impact on TSEnr and RPSFTMnr 
was larger ± both produced reduced bias when poor prognosis patients were more likely to switch. In general, 
the absolute impact of switching was reduced in scenarios where poor prognosis patients were more likely to 
switch.  
Key findings ± within method comparisons 
As shown by Figure 3, and as previously described, in scenarios where the complexity of the survivor function 
was moderate or high, with reducing hazards and a reducing treatment effect in the longer-term, the level of bias 
associated with TSE and TSEnr methods was often similar but, importantly, was in opposite directions. TSE 
consistently underestimated control group RMST, and TSEnr consistently overestimated control group RMST. 
In these scenarios only the size of the treatment effect and the switch proportion had substantial impacts on the 
bias associated with these methods. The TSEnr performed better when the switching proportion was low and, 
independently of this, when the treatment effect was small. The TSE method was relatively unaffected by the 
switch proportion but its performance was markedly improved when the treatment effect was low. The method 
that produced least bias varied, but, in general, TSEnr was more likely to produce least bias in scenarios where 
the treatment effect was high and the switching proportion was low ± in other scenarios TSE was more likely to 
produce least bias. However, TSEnr produced lower empirical SE and RMSE across all scenarios. 
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In scenarios in which the survivor function was simplified, with a constant treatment effect, both methods 
produced substantially lower bias ± with TSE generally producing marginally lower levels of bias (but higher 
RMSE) than TSEnr.  
The key findings associated with the RPSFTM and RPSFTMnr methods were similar ± but not identical ± to 
those found for TSE and TSEnr. In scenarios in which the complexity of the survivor function was moderate or 
high, biases were again in opposing directions, with the RPSFTM consistently underestimating, and RPSFTMnr 
consistently overestimating control group RMST. The size of the treatment effect and the switching proportion 
were again the most important determinants of bias, with the size of the treatment effect being most important 
for RPSFTM and the switching proportion being most important for RPSFTMnr. However, the method that 
produced least bias was much less variable, with the RPSFTMnr producing lower bias than RPSFTM in the vast 
majority of scenarios, with this only changing in some scenarios in which there was a low and common 
treatment effect. The RPSFTMnr produced lower RMSE and empirical SE in all scenarios.   
In scenarios in which the survivor function was simplified, bias was again substantially reduced for both 
methods, but RPSFTMnr continued to generally produce lower bias than RPSFTM.  
Key findings ± between method comparisons 
Across all scenarios the TSE, TSEnr and RPSFTMnr methods often produced bias of similar size, though TSEnr 
and RPSFTMnr consistently over-estimated control group RMST (thus underestimating treatment effects) and 
TSE consistently under-estimated control group RMST (thus overestimating treatment effects). The RPSFTM 
consistently produced higher levels of bias unless there was a low and common treatment effect. The TSE 
produced least percentage bias most often, particularly in scenarios characterised by a moderate or highly 
complex survivor function and a moderate switching proportion, or a low switching proportion combined with a 
low treatment effect (see Table 3). The RPSFTMnr produced least bias in the majority of scenarios when the 
switching proportion was low combined with a high treatment effect. However, TSEnr produced the lowest 
RMSE across all scenarios and methods that did not apply re-censoring always produced lower empirical SE 
and RMSE than those that did apply re-censoring.  
DISCUSSION  
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Our study demonstrates that adjustment analyses should be conducted both with and without re-censoring. Re-
censored and non-re-censored analyses are likely to often produce bias in opposing directions, potentially 
providing additional information on where the true treatment effect is likely to lie. There are three main factors 
that dictate the size and direction of bias associated with TSE, TSEnr, RPSFTM and RPSFTMnr methods when 
the objective is to estimate long-term survival times: the complexity of the survivor function; the size of the 
treatment effect; and the switching proportion. In addition, we found that the RPSFTM produced higher levels 
of bias than the other adjustment methods in the majority of scenarios.  
When the survivor function is simple, with monotonic hazards over time and a constant treatment effect, re-
censoring is relatively unimportant. All methods generally produce low levels of bias and differences in their 
estimates are generally small and are driven mainly by whether or not methodological assumptions such as the 
common treatment effect assumption hold. Re-censoring in and of itself does not result in bias if accurate 
extrapolations can be achieved from shorter-term data, which is more likely when survivor functions are 
characterised by long-term trends that are established in the short-term. On a case-by-case basis, this may not be 
straightforward to determine, but could be informed by comparisons between the re-censored and the non-re-
censored dataset, and by analysing the long-term hazards observed in the experimental group ± as trends in the 
hazards observed in long-term survivors in the experimental group might also be expected in long-term 
survivors in the control group.  
Complex hazard functions with changing trends over time and turning points have been presented in the 
literature for breast cancer.[27,28], and the presence of long-term survivors has been noted for several other 
cancer types, such as melanoma, head and neck cancer and myeloid leukaemia, particularly with the advent of 
new immuno-oncology treatments.[29] It therefore seems likely that there will often be important time-
dependent changes in the hazard function representing cohorts of cancer patients. This is why we concentrated 
our simulations on scenarios with complex hazard functions and it is therefore important to focus discussion of 
the re-censoring issue on circumstances where the survivor function is complex. 
When the survivor function is complex, with a hazard that initially rises before falling over time, and with a 
time-dependent treatment effect, methods that re-censor are likely to produce bias in opposite directions to 
methods that do not re-censor when estimating longer term mean survival. In isolation, this is an important 
finding. We have demonstrated that extrapolating from re-censored data leads to under-estimates of long-term 
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survival in groups affected by switching. Conversely, the informative censoring associated with not re-censoring 
leads to over-estimates of long-term survival in groups affected by switching.  
Further, we have shown that the most important determinant of performance for methods that re-censor is the 
size of the treatment effect. This is logical ± re-censoring results in more lost information when the treatment 
effect is high, reducing the probability that long-term trends in the hazard function are established within the re-
censored dataset. For methods that do not re-censor the size of the treatment effect and the switching proportion 
are of most importance. This also makes sense ± not re-censoring leads to less informative censoring when the 
switching proportion is low, and to less substantial informative censoring when the treatment effect is small.  
Our intention was primarily to compare re-censored and non-re-censored analyses within the RPSFTM and TSE 
classes. However, our results also provide new information allowing us to update the comparison between these 
two classes. Whilst no single method produced least percentage bias consistently across all scenarios, TSEnr 
produced the lowest empirical SE and RMSE of the adjustment methods in all 96 scenarios, suggesting that 
when bias and variability are considered together, it consistently represented the optimal method. In addition, 
the RPSFTM (with re-censoring) performed substantially worse than other adjustment methods in a subset of 
scenarios, allowing scenarios to be identified in which this method should not be relied upon. 
The RPSFTM with re-censoring consistently produced negative bias (over-estimating the treatment effect) and 
performed substantially worse than other adjustment methods in scenarios with a high treatment effect and a 
complex survivor function, particularly when there was not a common treatment effect. When the survivor 
function is characterised by hazards that begin to fall in the longer term, re-censoring causes a negative bias if 
the trend in the hazards is not established before the re-censoring time-point. In addition, when switchers receive 
a decreased treatment effect the RPSFTM ± which assumes a common treatment effect ± will over-adjust 
survival times for switchers, causing an additional negative bias. Hence, the RPSFTM with re-censoring is 
prone to two sources of negative bias in scenarios such as those investigated in this study ± two-thirds of 
scenarios incorporated a complex hazard function with decreasing hazards in the longer term, and half 
incorporated a violation of the common treatment effect assumption, where switchers received a reduced 
treatment effect. The TSE is only prone to one of these sources of bias because it does not assume a common 
treatment effect, which explains why the TSE consistently produced more conservative estimates of restricted 
mean survival than the RPSFTM. 
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If, in reality, hazards are expected to decline over time, both the RPSFTM and TSE with re-censoring are likely 
to lead to under-estimates of longer-term control group survival. If, in addition, switchers receive a decreased 
treatment effect, the RPSFTM with re-censoring is likely to lead to even more serious under-estimates of longer-
term control group survival. Overall, the TSE appears to represent a better method than the RPSFTM for 
adjusting for treatment switching unless the treatment effect is common and constant, provided the switching 
mechanism matches the requirements of the TSE method.  
When re-censoring is not applied within RPSFTM and TSE adjustment methods, they are no longer exposed to 
the negative bias associated with a loss of longer-term information in the presence of hazards that decrease over 
time. The RPSFTMnr remains exposed to the negative bias associated with a non-common treatment effect and 
both methods become exposed to bias associated with informative censoring. Originally we hypothesised that 
informative censoring would be associated with positive bias (over-estimates of control group survival) when 
poor prognosis patients were more likely to switch treatments ± because more poor prognosis patients would be 
censored at earlier time-points than good prognosis patients. Conversely, when good prognosis patients were 
more likely to switch we expected that not re-censoring would lead to negative bias (under-estimates of control 
group survival), because good prognosis patients would generally be censored at earlier time-points. In fact, in 
scenarios where there was a complex survivor function, RPSFTMnr and TSEnr almost always produced positive 
bias, irrespective of the prognosis of switchers.  
After thorough investigation, we conclude that this will occur when there are any non-switching long-term 
survivors (see Appendix H for more details). These patients most influence the impact of informative censoring, 
because re-censoring primarily affects the right-hand-side of the Kaplan-Meier curve. It is this that causes the 
methods that do not re-censor to result in bias in the opposite direction to that produced by methods that re-
censor.  
Which bias is greater depends partly on scenario characteristics and partly on whether the TSE or RPSFTM 
adjustment method is used. In our simulations TSE and TSEnr often produced similarly low levels of bias, in 
opposite directions, but there was a trend towards TSE being likely to produce less bias than TSEnr unless the 
treatment effect was high (HR approximately 0.56 as opposed to 0.80) and the switching proportion was low 
(approximately 25% of eligible patients as opposed to 55%). However, the TSEnr always produced lower 
empirical SE and RMSE than TSE and therefore may still be preferred when the aim is to estimate long-term 
treatment effects. 
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More confident conclusions may be made about which of the RPSFTM and RPSFTMnr analyses are likely to 
produce least bias. When there is a complex survivor function with reducing long-term hazards and when the 
common treatment effect assumption does not hold, the RPSFTMnr is subject to opposing forces of bias ± 
violation of the common treatment effect assumption induces negative bias, whereas informative censoring is 
likely to cause positive bias. Conversely, the RPSFTM is prone to the dual negative biases associated with re-
censoring and a non-common treatment effect. Whilst the RPSFTM is likely to result in appreciable negative 
bias in these scenarios, the direction of bias associated with the RPSFTMnr depends upon the extent to which 
negative and positive biases cancel out. Given that these biases are likely to cancel out to some extent, it seems 
reasonable to conclude that the RPSFTMnr is likely to produce lower bias than the RPSFTM in these scenarios 
± as was almost exclusively the case in our simulations. The RPSFTMnr also consistently produced lower 
empirical SE and RMSE than RPSFTM and therefore may generally be preferred when the aim is to estimate 
long-term treatment effects. The competing biases associated with the RPSFTMnr also explain why this method 
generally produced marginally lower percentage bias than the TSEnr in scenarios where the common treatment 
effect assumption did not hold, and very similar levels of percentage bias when the common treatment effect 
assumption did hold.  
We are aware of three studies that have presented analyses adjusting for treatment switching both with and 
without re-censoring, or which have investigated the impact of re-censoring. White et al. (1999) presented 
RPSFTM analyses undertaken on the Concorde trial of immediate versus deferred zidovudine for patients with 
HIV. The analysis without re-censoring led to more conservative estimates of the treatment effect and the 
authors observed that the treatment effect appeared to decrease over time. They concluded that their re-censored 
analysis may have over-estimated the treatment effect, whilst their non-re-censored analysis may have produced 
an under-estimate because switchers appeared to have a better prognosis than non-switchers.[17] Latimer et al. 
reported an adjustment analysis applied to an RCT comparing trametinib and chemotherapy in patients with 
metastatic melanoma.[11] RSPFTM and two-stage analyses which excluded re-censoring produced the most 
conservative estimates of the treatment effect. The authors found evidence of a decreasing treatment effect over 
time, and concluded that the analyses that excluded re-censoring were likely to be least biased. The pattern in 
WKHVHUHVXOWVLVLGHQWLFDOWRWKDWVHHQLQRXUVWXG\7KLVZDVQRWWKHFDVHLQ:KLWHDQG*RHWJKHEHXU¶VDQDO\VLVRI
an RCT comparing two anti-hypertensive treatments affected by treatment switching. Heavily re-censored 
analyses resulted in less optimistic estimates of the treatment effect, because the treatment effect only became 
apparent in the long-term.[20] It is possible that in some situations the treatment effect may rise and then fall 
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over time ± in fact this was the pattern simulated in our scenarios (see Figure 2). If re-censoring leads to 
analyses being based on data observed before the treatment effect becomes apparent, under-estimates of the 
long-term treatment effect may result. This was not the case in our simulations, but with a more delayed 
treatment effect it is conceivable. 
Previous authors have noted that failing to re-censor may result in a small bias but a large gain in precision.[17] 
We found that failing to re-censor often led to a large gain in precision and reduced bias. RMSE and empirical 
SE were substantially reduced when re-censoring was excluded from RPSFTM and TSE analyses, highlighting 
important advantages associated with not re-censoring. 
Our study has limitations. We sought to investigate many realistic scenarios, but a simulation study can never be 
exhaustive. Our choice of endpoint could also be questioned ± whilst we used restricted means to limit the 
impact of extrapolation on our results,  extrapolation may still have introduced an additional bias for methods 
that re-censored, because for these methods extrapolation was required to estimate RMST at 548 days. 
However, this bias is attributable to the adjustment method, because re-censoring enforces a loss of information 
which makes the estimation of long-term survival more difficult. Because we used restricted rather than 
unrestricted mean survival as our performance measure the impact of extrapolation is limited in our study. HTA 
agencies typically require estimates of unrestricted mean survival. We expect that all adjustment methods would 
have produced increased bias if we had used this as our performance measure ± with methods that re-censor 
likely to be most seriously affected owing to the associated loss of information. However, this would have 
shifted the emphasis of our study onto methods for extrapolating survival data, rather than methods for adjusting 
for treatment switching. We could instead have chosen to use a mean restricted to a shorter time-period, to 
prevent the results of re-censored analyses from being affected by extrapolation. However, given that our 
intention is to help inform the choice of adjustment method used primarily within HTA analyses we deemed it 
of little value to assess the performance of the different adjustment methods in estimating short-term treatment 
effects. Another option would have been to compare bias in the estimated difference in mean survival in the 
control group and the experimental group. We felt that concentrating solely on control group mean survival 
provided a more direct assessment of the adjustment methods, since they only made adjustments to the control 
group. However, it is relevant to note that this may make biases seem less important than they actually are. For 
instance, in Scenarios 13 and 61, a 1% bias in control group RMST is equivalent to a bias of approximately 5% 
in the difference between control group and experimental group RMST. In Scenarios 9 and 57 this is further 
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inflated ± with a 1% bias in control group RMST equivalent to a bias of approximately 10% in the estimated 
RMST difference. 
Also, we recognise that results of survival analyses are usually summarised as hazard ratios. The majority of our 
scenarios had non-proportional hazards so HRs were inappropriate for measuring performance. Despite this, we 
GLGFDOFXODWHµDYHUDJH¶+5VWRDOORZDVVHVVPHQWRIDGMXVWHG+5s. This is presented in Appendix I. We found 
that estimates of HRs were prone to higher levels of bias than estimates of restricted mean survival ± 
particularly if there is a complex survivor function and a time-dependent treatment effect and re-censoring is 
used. This should be borne in mind if adjustment analyses are summarised using HRs. 
Finally, as with previous simulation studies on switching adjustment methods, we did not incorporate 
bootstrapping for confidence intervals of RMST estimates.[21,22] Coverage levels associated with the 
adjustment analyses are correspondingly poor because confidence intervals only took into account uncertainty in 
the treatment effect ± not the uncertainty in the underlying survival distribution. For this reason, we have not 
presented detailed coverage results. In reality, the entire adjustment process should be bootstrapped to obtain 
appropriate confidence intervals.  
We have shown that both re-censored and non-re-censored adjustment analyses are prone to bias, depending 
upon scenario characteristics. Our study provides valuable information on the likely direction and extent of 
these biases, and on their variability. Analyses that exclude re-censoring are likely to produce under-estimates of 
the treatment effect, irrespective of the perceived prognosis of switchers. Re-censored analyses are likely to 
produce over-estimates of the treatment effect if the treatment effect decreases over time, especially RPSFTM 
analyses if switchers receive a reduced treatment effect. Whilst we found that TSE, TSEnr and RPSFTMnr 
analyses often produced similar levels of bias, the choice of method remains important because the bias 
associated with re-censored and non-re-censored analyses is likely to be in opposite directions. Our results can 
be used to enable better interpretation of treatment switching adjustment analyses, by helping determine a range 
in which the true treatment effect is likely to lie. We suggest that analyses should be conducted with and without 
re-censoring, and that re-censoring should not always represent the default approach when the objective is to 
estimate long-term survival times and treatment effects. In the context of HTA, decision-makers are likely to 
choose one adjustment method to inform their base case estimate of the cost-effectiveness of a novel treatment. 
However, being aware of the sensitivity of this estimate to the adjustment method chosen could importantly 
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influence decision-making, providing either reassurance or concern. This additional information could therefore 
helpfully impact upon decisions made on access to novel treatments around the world. 
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Table 1:  Scenarios 9 and 13 ± performance measures for estimation of control arm RMST 
Scenario details Method Percent bias Empirical SE of % bias  RMSE of % bias  Coverage (%) Convergence (%) 
Scenario number: 9 
True RMST: 
    Control:  357 
    Experimental:  391 
Mean switch: 25% 
True ave. HR: 0.81 
True ave. AF: 1.19 
Mean censored: 40% 
Switcher treatment effect: 
    20% reduction 
No switching 0.8 3.6 3.6 95.6 100 
ITT 1.2 3.6 3.8 94.8 100 
TSE -0.3 4.3 4.3 49.4 100 
TSEnr 0.7 3.7 3.7 29.2 100 
RPSFTM -1.2 5.5 5.6 37.7 100 
RPSFTMnr 0.4 4.0 4.1 19.4 100 
min/max MC error 0.1/0.2 0.1/0.1 0.1/0.2 0.6/1.6 - 
Scenario number: 13 
True RMST: 
    Control:  357 
    Experimental:  430 
Mean switch: 25% 
True ave. HR: 0.57 
True ave. AF: 1.53 
Mean censored: 48% 
Switcher treatment effect: 
    20% reduction 
No switching 0.1 3.7 3.7 94.6 100 
ITT 2.8 3.6 4.5 90.0 100 
TSE -1.6 5.7 5.9 53.5 100 
TSEnr 1.4 3.7 4.0 24.7 100 
RPSFTM -3.8 7.2 8.2 36.3 100 
RPSFTMnr 0.9 4.1 4.2 17.2 100 
min/max MC error 0.1/0.2 0.1/0.2 0.1/0.2 0.7/1.6 - 
Note: RMST: restricted mean survival time; HR: hazard ratio; AF: acceleration factor; SE: standard error; RMSE: root mean squared error; MC: Monte-Carlo; ITT: intention 
to treat; TSE: two-stage estimation; TSEnr: two-stage estimation without re-censoring; RPSFTM: rank preserving structural failure time model; RPSFTMnr: rank preserving 
structural failure time model without re-censoring 
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Table 2:  Scenarios 57 and 61 ± performance measures for estimation of control arm RMST 
Scenario details Method 
Bias (% of true 
RMST) 
Empirical SE  (% of 
true RMST)  
RMSE  (% of true 
RMST) Coverage (%) Convergence (%) 
Scenario number: 57 
True RMST: 
    Control:  357 
    Experimental:  391 
Mean switch: 57% 
True ave. HR: 0.81 
True ave. AF: 1.19 
Mean censored: 40% 
Switcher treatment effect: 
    20% reduction 
No switching 0.2 3.6 3.6 96.0 100 
ITT 2.6 3.6 4.4 89.5 100 
TSE -1.1 5.2 5.3 67.2 100 
TSEnr 0.8 4.0 4.1 48.6 100 
RPSFTM -2.0 7.3 7.6 66.5 100 
RPSFTMnr 0.7 5.0 5.0 46.7 100 
min/max MC error 0.1/0.2 0.1/0.2 0.1/0.2 0.6/1.6 - 
Scenario number: 61 
True RMST: 
    Control:  357 
    Experimental:  430 
Mean switch: 57% 
True ave. HR: 0.57 
True ave. AF: 1.53 
Mean censored: 49% 
Switcher treatment effect: 
    20% reduction 
No switching 0.2 3.8 3.8 94.3 100 
ITT 6.5 3.6 7.5 58.8 100 
TSE -1.9 6.6 6.9 66.8 100 
TSEnr 3.0 4.0 5.0 33.6 100 
RPSFTM -5.3 9.3 10.7 56.8 100 
RPSFTMnr 2.1 5.1 5.5 36.0 100 
min/max MC error 0.1/0.3 0.1/0.2 0.1/0.3 0.7/1.6 - 
 
Note: RMST: restricted mean survival time; HR: hazard ratio; AF: acceleration factor; SE: standard error; RMSE: root mean squared error; MC: Monte-Carlo; ITT: intention 
to treat; TSE: two-stage estimation; TSEnr: two-stage estimation without re-censoring; RPSFTM: rank preserving structural failure time model; RPSFTMnr: rank preserving 
structural failure time model without re-censoring  
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Table 3: Methods producing least bias 
 
Complexity of survivor function: simple Complexity of survivor function: moderate/high 
Total 
Low switch proportion Moderate switch proportion Low switch proportion Moderate switch proportion 
Low 
treatment 
effect 
High 
treatment 
effect 
Low 
treatment 
effect 
High 
treatment 
effect 
Low 
treatment 
effect 
High 
treatment 
effect 
Low 
treatment 
effect 
High 
treatment 
effect 
Scenarios 1-4, 25-28 5-9, 29-32 49-52, 73-76 53-56, 77-80 
9-12, 17-20, 
33-36, 41-44 
13-16, 21-24, 
37-40, 45-48 
57-60, 65-68, 
81-84, 89-92 
61-64, 69-72, 
85-88, 93-96 All 
ITT 0 0 0 0 0 0 0 0 0 
TSE 2 4 2 3 8 0 9 9 36 
TSEnr 0 1 2 2 2 3 1 2 13 
RPSFTM 1 1 3 2 2 0 3 0 12 
RPSFTMnr 5 3 1 1 4 13 3 5 35 
Note: ITT: intention to treat; TSE: two-stage estimation; TSEnr: two-stage estimation without re-censoring; RPSFTM: rank preserving structural failure time 
model; RPSFTMnr: rank preserving structural failure time model without re-censoring 
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Figure 1. Trametinib compared to chemotherapy for metastatic melanoma: overall survival in primary efficacy population. (A). Rank-preserving structural failure time 
models (RPSFTM) with re-censoring. (B). RPSFTM without re-censoring. (C). Two-stage method with re-censoring. (D). Two-stage method without re-censoring. 
Reproduced from Latimer et al, 2016 [11]  
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Figure 2. One simulated dataset from Scenario 13 with no switching: (a) Overall survival Kaplan±Meier (b) Smoothed hazard rate  
(a)                                                                                               (b) 
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Figure 3. Percentage bias across all scenarios 
 
Note: ITT: intention to treat; TSE: two-stage estimation; TSEnr: two-stage estimation without re-censoring; RPSFTM: rank preserving structural failure time model; 
RPSFTMnr: rank preserving structural failure time model without re-censoring; CTE: common treatment effect; HR: hazard ratio 
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Figure 4. Empirical standard error across all scenarios 
 
Note: ITT: intention to treat; TSE: two-stage estimation; TSEnr: two-stage estimation without re-censoring; RPSFTM: rank preserving structural failure time model; 
RPSFTMnr: rank preserving structural failure time model without re-censoring; CTE: common treatment effect; HR: hazard ratio 
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Figure 5. Root mean squared error across all scenarios 
 
Note: ITT: intention to treat; TSE: two-stage estimation; TSEnr: two-stage estimation without re-censoring; RPSFTM: rank preserving structural failure time model; 
RPSFTMnr: rank preserving structural failure time model without re-censoring; CTE: common treatment effect; HR: hazard ratio 
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